Clinicopathological characteristics of extremely young Korean multiple myeloma patients: Therapeutic implications

Junghoon Shin, Youngil Koh, Jeonghwan Youk, Miso Kim, Byung Soo Kim, Chul Won Choi, Hwa Jung Sung, Yong Park, Sung Soo Yoon, Inho Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background/Aims: Although multiple myeloma (MM) is typically a disease of the elderly, a certain subset of extremely young patients exists. It is necessary to establish clinicopathological characteristics for this population. Methods: We reviewed the medical records of MM patients whose age was 40 years or younger at diagnosis. Results: A total of 32 patients were analyzed (male to female ratio 19:13, median age 37 years). According to International Staging System, 29%, 48%, and 16% were in stage I, II, and III, respectively. Light chain myeloma accounted for 30%. Clinically significant anemia, hypercalcemia, azotemia, and hypoalbuminemia were present in 29%, 28%, 13%, and 28%, respectively. Three or more lytic bone lesions were detected in 45% of the patients, whereas 13% had no lytic bone lesions. Regarding treatment, 79% of patients received autologous hematopoietic stem cell transplantation. After a median follow-up duration of 64 months, the 1-, 3-, and 5-year overall survival (OS) rates were 84%, 62%, and 54%, respectively. The median OS was 61 months for the entire cohort. Conclusions: In our study, MM patients aged 40 years or younger at diagnosis showed no superior survival compared to those of the moderately elderly patients based on historical data.

Original languageEnglish
Pages (from-to)722-730
Number of pages9
JournalKorean Journal of Internal Medicine
Volume32
Issue number4
DOIs
Publication statusPublished - 2017 Jul 1

Fingerprint

Multiple Myeloma
Therapeutics
Azotemia
Bone and Bones
Hypoalbuminemia
Survival
Hematopoietic Stem Cell Transplantation
Hypercalcemia
Population Characteristics
Medical Records
Anemia
Survival Rate
Light

Keywords

  • Hematopoietic stem cell transplantation
  • Multiple myeloma
  • Treatment outcome
  • Young adult

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Clinicopathological characteristics of extremely young Korean multiple myeloma patients : Therapeutic implications. / Shin, Junghoon; Koh, Youngil; Youk, Jeonghwan; Kim, Miso; Kim, Byung Soo; Choi, Chul Won; Sung, Hwa Jung; Park, Yong; Yoon, Sung Soo; Kim, Inho.

In: Korean Journal of Internal Medicine, Vol. 32, No. 4, 01.07.2017, p. 722-730.

Research output: Contribution to journalArticle

@article{2c29be0423954aee8ed9bdf63ea8ea3c,
title = "Clinicopathological characteristics of extremely young Korean multiple myeloma patients: Therapeutic implications",
abstract = "Background/Aims: Although multiple myeloma (MM) is typically a disease of the elderly, a certain subset of extremely young patients exists. It is necessary to establish clinicopathological characteristics for this population. Methods: We reviewed the medical records of MM patients whose age was 40 years or younger at diagnosis. Results: A total of 32 patients were analyzed (male to female ratio 19:13, median age 37 years). According to International Staging System, 29{\%}, 48{\%}, and 16{\%} were in stage I, II, and III, respectively. Light chain myeloma accounted for 30{\%}. Clinically significant anemia, hypercalcemia, azotemia, and hypoalbuminemia were present in 29{\%}, 28{\%}, 13{\%}, and 28{\%}, respectively. Three or more lytic bone lesions were detected in 45{\%} of the patients, whereas 13{\%} had no lytic bone lesions. Regarding treatment, 79{\%} of patients received autologous hematopoietic stem cell transplantation. After a median follow-up duration of 64 months, the 1-, 3-, and 5-year overall survival (OS) rates were 84{\%}, 62{\%}, and 54{\%}, respectively. The median OS was 61 months for the entire cohort. Conclusions: In our study, MM patients aged 40 years or younger at diagnosis showed no superior survival compared to those of the moderately elderly patients based on historical data.",
keywords = "Hematopoietic stem cell transplantation, Multiple myeloma, Treatment outcome, Young adult",
author = "Junghoon Shin and Youngil Koh and Jeonghwan Youk and Miso Kim and Kim, {Byung Soo} and Choi, {Chul Won} and Sung, {Hwa Jung} and Yong Park and Yoon, {Sung Soo} and Inho Kim",
year = "2017",
month = "7",
day = "1",
doi = "10.3904/kjim.2016.256",
language = "English",
volume = "32",
pages = "722--730",
journal = "Korean Journal of Internal Medicine",
issn = "0494-4712",
publisher = "Korean Association of Internal Medicine",
number = "4",

}

TY - JOUR

T1 - Clinicopathological characteristics of extremely young Korean multiple myeloma patients

T2 - Therapeutic implications

AU - Shin, Junghoon

AU - Koh, Youngil

AU - Youk, Jeonghwan

AU - Kim, Miso

AU - Kim, Byung Soo

AU - Choi, Chul Won

AU - Sung, Hwa Jung

AU - Park, Yong

AU - Yoon, Sung Soo

AU - Kim, Inho

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Background/Aims: Although multiple myeloma (MM) is typically a disease of the elderly, a certain subset of extremely young patients exists. It is necessary to establish clinicopathological characteristics for this population. Methods: We reviewed the medical records of MM patients whose age was 40 years or younger at diagnosis. Results: A total of 32 patients were analyzed (male to female ratio 19:13, median age 37 years). According to International Staging System, 29%, 48%, and 16% were in stage I, II, and III, respectively. Light chain myeloma accounted for 30%. Clinically significant anemia, hypercalcemia, azotemia, and hypoalbuminemia were present in 29%, 28%, 13%, and 28%, respectively. Three or more lytic bone lesions were detected in 45% of the patients, whereas 13% had no lytic bone lesions. Regarding treatment, 79% of patients received autologous hematopoietic stem cell transplantation. After a median follow-up duration of 64 months, the 1-, 3-, and 5-year overall survival (OS) rates were 84%, 62%, and 54%, respectively. The median OS was 61 months for the entire cohort. Conclusions: In our study, MM patients aged 40 years or younger at diagnosis showed no superior survival compared to those of the moderately elderly patients based on historical data.

AB - Background/Aims: Although multiple myeloma (MM) is typically a disease of the elderly, a certain subset of extremely young patients exists. It is necessary to establish clinicopathological characteristics for this population. Methods: We reviewed the medical records of MM patients whose age was 40 years or younger at diagnosis. Results: A total of 32 patients were analyzed (male to female ratio 19:13, median age 37 years). According to International Staging System, 29%, 48%, and 16% were in stage I, II, and III, respectively. Light chain myeloma accounted for 30%. Clinically significant anemia, hypercalcemia, azotemia, and hypoalbuminemia were present in 29%, 28%, 13%, and 28%, respectively. Three or more lytic bone lesions were detected in 45% of the patients, whereas 13% had no lytic bone lesions. Regarding treatment, 79% of patients received autologous hematopoietic stem cell transplantation. After a median follow-up duration of 64 months, the 1-, 3-, and 5-year overall survival (OS) rates were 84%, 62%, and 54%, respectively. The median OS was 61 months for the entire cohort. Conclusions: In our study, MM patients aged 40 years or younger at diagnosis showed no superior survival compared to those of the moderately elderly patients based on historical data.

KW - Hematopoietic stem cell transplantation

KW - Multiple myeloma

KW - Treatment outcome

KW - Young adult

UR - http://www.scopus.com/inward/record.url?scp=85025129945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025129945&partnerID=8YFLogxK

U2 - 10.3904/kjim.2016.256

DO - 10.3904/kjim.2016.256

M3 - Article

C2 - 28651310

AN - SCOPUS:85025129945

VL - 32

SP - 722

EP - 730

JO - Korean Journal of Internal Medicine

JF - Korean Journal of Internal Medicine

SN - 0494-4712

IS - 4

ER -